BiotechTube

Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil

Phase 2UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC

Conditions

The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC

Trial Timeline

May 8, 2023 → Oct 1, 2024

NCT ID
NCT05947201

About Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil

Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil is a phase 2 stage product being developed by Akeso for The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC. The current trial status is unknown. This product is registered under clinical trial identifier NCT05947201. Target conditions include The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC.

What happened to similar drugs?

2 of 3 similar drugs in The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC were approved

Approved (2) Terminated (0) Active (1)
✅LetrozoleNovartisApproved
✅Cannabidiol (Epidiolex)Jazz PharmaceuticalsApproved
🔄DenosumabAmgenPhase 3

Hype Score Breakdown

Clinical
12
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05947201Phase 2UNKNOWN

Competing Products

5 competing products in The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC

See all competitors
ProductCompanyStageHype Score
Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) + Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) + 0.9% natural salineJohnson & JohnsonPre-clinical
22
Dalpicilib + Abiraterone Acetate (II) + Androgen Deprivation Therapy + PrednisoneJiangsu Hengrui MedicinePhase 2
42
LetrozoleNovartisApproved
39
DenosumabAmgenPhase 3
40
Cannabidiol (Epidiolex)Jazz PharmaceuticalsApproved
40